Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma

Journal of the Formosan Medical Association

Volumn 103, Issue 6, 2004, Pages 442-447

  Chen, Cheng Hsiung ^a   Chen, Jung Fu ^a   Yang, Bor Yan ^a   Liu, Rue Tsuan ^a   Tung, Shih Chen ^a   Chien, Wen Yen ^a   Lu, Yung Chuan ^a   Kuo, Ming Chun ^a   Hsieh, Ching Jung ^a   Wang, Pei Wen ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Adenocarcinoma; Bone density; Lumbar vertebrae, radiography; Thyroid neoplasms; Thyroxine

Indexed keywords

CALCIUM; IODINE 131; LEVOTHYROXINE; PHOSPHATE; THYROTROPIN; THYROXINE;

ADULT; AGED; ARTICLE; BODY MASS; BONE DENSITY; BONE MINERAL; CALCIUM BLOOD LEVEL; CANCER RECURRENCE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE REGIMEN; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; HIP; HUMAN; LONG TERM CARE; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSTEOPOROSIS; PATIENT MONITORING; PHOSPHATE BLOOD LEVEL; POSTMENOPAUSE; PREMENOPAUSE; RETROSPECTIVE STUDY; STUDENT T TEST; TAIWAN; THYROID CARCINOMA; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL; ADENOCARCINOMA; BLOOD; DRUG EFFECT; MIDDLE AGED; RADIODENSITOMETRY; THYROID TUMOR;

ADENOCARCINOMA; ADULT; BONE DENSITY; DENSITOMETRY, X-RAY; FEMALE; HUMANS; MIDDLE AGED; TAIWAN; THYROID NEOPLASMS; THYROTROPIN; THYROXINE;

EID: 4444324979     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. von Recklinghausen FC: Die fibrose cider deformierende Ostitis, die Osteomalazie und die osteoplastische Carzinose in ihren gegenseitigen Beziehungen. In: Festschrift Rudolph Virchow. Berlin: George Reimer, 1891;1:20-89.
2. Mosekilde L, Eriksen EF, Charles P: Effects of thyroid hormone on bone and mineral metabolism. Endocrinol Metab Clin North Am 1990,19:35-63.
3. Ross DS: Hyperthyroidism, thyroid hormone therapy, and bone. Thyroid 1994;4:319-6.
4. Cooper DS, Specker B, Ho M, et al: Thyrotropin suppression and disease progression in patients with differentiated thyroid cancers: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 1998;8:737-44.
5. Mazzaferri EL, Jhiang SM: Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-28.
6. Biondi B, Fazio S, Carella C, et al: Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1993;77:334-8.
7. Banovac K, Papic M, Bilsker MS, et al: Evidence of hyperthyroidism in apparently euthyroid patients treated with levothyroxine. Arch Intern Med 1989;149:809-12.
8. Diamond T, Nery L, Hales I: A therapeutic dilemma: suppressive doses of thyroxine significantly reduced bone mineral measurement in both premenopausal and postmenopausal women with thyroid carcinoma. J Clin Endocrinol Metab 1990; 72:1184-8.
9. Dulgeroff AJ, Hershman JM: Medical therapy for differentiated thyroid carcinoma. Endocr Rev 1994;15:500-15.
10. Wartofsky L: Use of sensitive TSH assay to determine optimal thyroid hormone therapy and avoid osteoporosis. Annu Rev Med 1991;42:341-5.
11. Reeve TS, Delbridge L, Crummer P: Total thyroidectomy in the management of differentiated thyroid cancer: a review of 258 cases. Aust N Z J Surg 1986;56:829-33.
12. Samaan NA, Maheshwari YK, Nader S, et al: Impact of therapy for differentiated carcinoma of the thyroid: an analysis of 706 cases. J Clin Endocrinol Metab 1983,56:1131-8.
13. Muller CG, Bayley TA, Harrison JE, et al: Possible limited bone loss with suppressive thyroxine therapy is unlikely to have clinical relevance. Thyroid 1995;5:81-7.
14. Franklyn JA, Betteridge J, Daykin J, et al: Long-term thyroxine treatment and bone mineral density. Lancet 1992;340:9-13.
15. Marcocci C, Golia F, Bruno-Bossio G, et al: Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women. J Clin Endocrinol Metab 1994, 78:818-23.
16. Garton M, Reid I, Loveridge S, et al: Bone mineral density and metabolism in premenopausal women taking L-thyroxine replacement therapy. Clin Endocrinol (Oxf) 1994;41:747-55.
17. Gorres G, Kaim A, Otte A, et al: Bone mineral density in patients receiving suppressive doses of thyroxine for differentiated thyroid carcinoma. Eur J Nucl Med 1996;23:690-2.
18. Rosa GD, Testa A, Maussier ML, et al: A slightly suppressive dose of L-thyroxine does not affect bone turnover and bone mineral density in pre- and postmenopausal women with nontoxic goiter. Horm Metab Res 1995;27:503-7.
19. Taelman P, Kaufman JM, Janssens X, et al: Reduced forearm bone mineral content and biochemical evidence of increased bone turnover in women with euthyroid goiter treated with thyroid hormone. Clin Endocrinol (Oxf) 1990;33: 107-17.
20. Paul TL, Kerrigan J, Kelly AM, et al: Long-term L-thyroxine therapy is associated with decreased hip bone density in premenopausal women. JAMA 1988;259:3137-41.
21. Pioli G, Pedrazzoni M, Palummeri E, et al: Longitudinal study of bone loss after thyroidectomy and suppressive thyroxine therapy in premenopausal women. Acta Endocrinol (Copenh) 1992,126: 238-42.
22. McDermott MT, Perloff JJ, Kidd GS: A longitudinal assessment of bone loss in women with levothyroxine-suppressed benign thyroid disease and thyroid cancer. Calcif Tissue Int 1995;56: 521-5.
23. Schneider DL, Barrett-Connor EL, Morton DJ: Thyroid hormone use and bone mineral density in elderly women. Effect of estrogen. JAMA 1994;271:1245-9.
24. Kung AW, Lorentz T, Tam SC: Thyroxine suppressive therapy decreases bone mineral density in post-menopausal women. Clin Endocrinol (Oxf) 1993;39:535-40.
25. Adlin EV, Maurer AH, Marks AD, et al: Bone mineral density in postmenopausal women treated with L-thyroxine. Am J Med 1991;90:360-6.
26. Grant DJ, McMurdo ME, Mole PA, et al: Suppressed TSH levels secondary to thyroxine replacement therapy are not associated with osteoporosis. Clin Endocrinol (Oxf) 1993;39:529-33.
27. Ribot C, Tremollieres F, Pouilles JM, et al: Bone mineral density and thyroid hormone therapy. Clin Endocrinol (Oxf) 1990;33: 143-53.
28. Muneyyirci-Delale O, Nacharaju VL, Dalloul M, et aL: Serum ionized magnesium and calcium in women after menopause: inverse relation of estrogen with ionized magnesium. Fertil Steril 1999;71:869-72.
29. Uzzan B, Campos J, Cucherat M, et al: Effect on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 1996;81:4278-89.
30. Bauer DC, Ettinger B, Nevitt MC, for the Study of Osteoporotic Fractures Research Group: Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med 2001;134:561-8